Biopact

Deal To Watch
BETA

PATENTED TECHNOLOGY THAT MAKES FIGHTING DISEASE SIMPLER, FASTER AND CHEAPER.

Analytics

Raised to Date: $876,778

Aggregate Commitments $
Platform

Equifund CFP

Start Date

02/26/2020

Close Date

02/12/2021

Min. Goal

$20,000

Max. Goal

$1,070,000

Min. Investment

$465

Security Type

Equity - Common

Funding Type

RegCF

Series

Seed

Pre-Money Valuation

$30,000,000

Weekly Commitments $
Status

Active

Reporting Date

01/20/2021

Days Remaining

21

% of Min. Goal

4,384%

% of Max. Goal

82%

Likelihood of Max
Avg. Daily Raise

$2,665

# of Investors

764

Momentum
Location
Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B

Margin

High

Capital Intensity

High

Business Type

High Growth

Biopact Cellular Transport, with a valuation of $30 million, is raising funds on Equifund Crowd Funding Platform. The company has a unique patented intracellular delivery technology that transports gene-editing technologies to cells effectively, safely, and affordably. The delivery mechanism of Biopact Cellular Transport will help reduce the cost and increase the effectiveness of therapies like CRISPR, TALEN, and CAR-T. Biopact Cellular Transport was founded by Kurt Swogger and is led by Randy Kinsel as the President. The current crowdfunding round of the company has a minimum target of $20,000 and a maximum target of $1,070,000. Biopact Cellular Transport’s MGMR technology is protected by 77 patents worldwide and has the potential to revolutionize cellular medicines.

Summary Profit and Loss Statement
Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-59

$0

Summary Balance Sheet
Most Recent Year Prior Year

Cash

$3,041

$0

Accounts Receivable

$0

$0

Total Assets

$3,041

$0

Short-Term Debt

$0

$0

Long-Term Debt

$0

$0

Total Liabilities

$0

$0

Ratings

last updated 01/21/2021

Ratings Platform - Beta Trial

Our new ratings and analytics platform is currently in Beta. To gain access to the Beta platform features, upgrade to a Pro paid account and accept the Beta terms on any page.

For a limited time, use coupon code "TRYMERLIN20" for a free 20 day trial of Kingscrowd Pro and Merlin Beta. Your paid subscription will activate at the end of 20 days. Cancel anytime.

Analyst Report

Deal To Watch
Ratings Platform - Beta Trial

Our new ratings and analytics platform is currently in Beta. To gain access to the Beta platform features, upgrade to a Pro paid account and accept the Beta terms on any page.

For a limited time, use coupon code "TRYMERLIN20" for a free 20 day trial of Kingscrowd Pro and Merlin Beta. Your paid subscription will activate at the end of 20 days. Cancel anytime.
Other Deals

Millennial Fertility Co. on NetCapital

The Millennial Fertility Co. team has been selected as a “Deal to Watch” by KingsCrowd. This distinction is…

Crowd
Neurotez Inc. on NetCapital

Neurotez has been selected as a “Deal To Watch” by KingsCrowd. This distinction is reserved for deals selected…

Crowd
SanMelix Laboratories on StartEngine

The SanMelix Labs team has been selected as a “Top Deal” by KingsCrowd. This distinction is reserved for…

Crowd
Create your first portfolio
WELCOME TO YOUR OWN INVESTMENTS PORTFOLIO ON KINGSCROWD.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Add Biopact on Equifund CFP
Follow company
Follow Biopact on Equifund CFP